Search / 36 results found

from
to
  • Updated

MUNICH and MORRISVILLE, N.C., Jan. 25, 2022 /PRNewswire/ -- Metabolon Inc., through its wholly-owned subsidiary, Metabolon GmbH, announces a multi-year collaboration with the FinnGen study in Finland to provide metabolomics data for population health studies to improve understanding of human health. 

  • Updated

TUESDAY, Jan. 25, 2022 (HealthDay News) -- If you're wondering whether to intentionally expose yourself to the Omicron variant with the goal of developing immunity, the answer is absolutely not, experts say.

  • Updated

LONG ISLAND CITY, N.Y., Jan. 25, 2022 /PRNewswire/ -- Loki Therapeutics, a company developing next- generation therapeutics that leverage vaccination recall antigens to enhance longevity and treat immune-system related diseases, including cancer, today announced that it has secured seed financing led by Formic Ventures. With this additional funding, Loki has been able to raise a total of $2 million to date. Loki plans to utilize proceeds from the funding for the manufacturing of clinical grade materials and regulatory work to enable the company's first-in-human clinical trial.

  • Updated

The Pharma.AI platform combining deep generative models (GAN), reinforcement learning (RL), transformers, and other modern machine learning techniques enables the identification of novel targets, generation of novel molecules non-existent in the chemical space, and prediction of outcomes for clinical trials.

  • Updated

The Pharma.AI platform combining deep generative models (GAN), reinforcement learning (RL), transformers, and other modern machine learning techniques enables the identification of novel targets, generation of novel molecules non-existent in the chemical space, and prediction of outcomes for clinical trials.

  • Updated

The Pharma.AI platform combining deep generative models (GAN), reinforcement learning (RL), transformers, and other modern machine learning techniques enables the identification of novel targets, generation of novel molecules non-existent in the chemical space, and prediction of outcomes for clinical trials.

  • Updated

DALLAS, Jan. 24, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development today announced that the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation and Orphan Drug Designation for the company's drug candidate LP-184 for the treatment of pediatric patients with ATRT. LP-184 is being pursued as a potential new therapy across a range of genetically defined solid tumors, including pancreatic cancer, GBM (Glioblastoma Multiforme) and ATRT (Atypical Teratoid Rhabdoid Tumor).

  • Updated

Organic apples are difficult to grow in the Midwest because spring and summer rains promote diseases that are difficult to control using organic methods. Fungal and bacterial diseases damage leaves, defoliate trees, and blemish fruit. One way to control diseases is to grow the apples in plastic-covered “high tunnels” – unheated greenhouses.

  • Updated

TIFTON — Using proven production practices to fight disease in the field, Georgia farmers produce half the peanuts grown in the U.S. each year. Modern peanut varieties carry few genetic defenses against some of the more devastating diseases, so peanut farmers carefully consider when to plant, whether to irrigate and when to apply fungicide and insecticide to keep those diseases from infecting the plant.